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Research
Correspondence Sensitive Assessment of Activity of Takayasu’s Arteritisby Pentraxin3, a New BiomarkerTo the Editor: Takayasu’s arteritis (TA) is a chronic vasculitis
mainly involving the aorta and its main branches (1). The
erythrocyte sedimentation rate and C-reactive protein (CRP) level
have generally been used to monitor disease activity. In addition to
steroids and conventional immunosuppressants, new agents are
reported to be very effective for patients who are resistant to
steroids and other drugs (2). We occasionally experience patients
with inflammatory symptoms but without a significant increase in
CRP. It is often difficult to identify patients in whom a recurrence
develops after treatment with steroids and other immunosuppres-
sant drugs using conventional imaging tests and biomarkers.
Therefore, we need sensitive biomarkers to assess subtle TA
activity.
Pentraxins are a superfamily of conserved proteins characterized
by the pentraxin domain. CRP is recognized as a classic short
pentraxin, whereas pentraxin3 (PTX3) belongs to the long pen-
traxins. PTX3 is produced locally by a variety of tissues and cells,
such as vascular endothelial cells, macrophages, and neutrophils,
predominantly in response to proinflammatory signals.
Matrix metalloproteinases (MMPs) are a group of 20 zinc-
containing endopeptidases that are either secreted or expressed at
the cell surface of all main vascular cell types. These proteinases
degrade interstitial tissues during the process of vessel inflamma-
tion and repair.
We hypothesized that serum PTX3 and MMP levels could
be sensitive biomarkers of TA activity to detect patients in
whom a recurrence develops, even in the absence of an increase
in CRP.
We screened 41 consecutive patients (2 males and 39 females
aged 13 to 49 years; average, 31.9 years) with a diagnosis of TA.
The diagnosis was based on the presence of symptoms and signs of
ischemic and inflammatory large-vessel disease supported by mag-
netic resonance angiography (MRA). All patients fulfilled 3 of
he 1990 American College of Rheumatology criteria for TA
lassification (3). According to the patient clinical symptoms, 23
atients were classified as in the active phase (2 males and 21
emales aged 13 to 47 years; average, 27.5 years) as evidenced by
linical recurrences such as progression of arterial stenosis or
ilation on MRA and carotid artery ultrasound, worsening
umbness of the arms, continuous fever, arm pain with use, or
eck or jaw pain within 2 years of blood sampling. These
linical signs and symptoms were usually accompanied by an
ncrease in the serum CRP level, but some patients did not
how an increase 0.5 mg/dl. Febrile patients with apparent
auses were not considered as having a TA recurrence. All
atients in this group satisfied the National Institutes of Health
riteria for active TA disease (4). Eighteen patients were
ategorized as in the inactive phase (all were females aged 25 to
9 years; average, 37.6 years). Twenty healthy subjects (all werefemales age 19 to 45 years; average 30.3 years) were registered
as normal controls.
Circulating levels of high-sensitivity C-reactive protein (hsCRP),
PTX3, MMP-2, and MMP-3 were determined by enzyme-linked
immunosorbent assay. Patients in the active phase had significantly
higher levels of PTX3 than those in the inactive phase and
controls. There were no differences among the groups in serum
hsCRP, MMP-2, and MMP-3 levels (Fig. 1). Using the receiver-
operating characteristic curve, we determined the cutoff values
(hsCRP 1,734 ng/ml, PTX3 5.37 ng/ml) to determine the
sensitivity (SE), specificity (SP), and the area under the receiver-
operating characteristic curve (hsCRP: SE 65.2%, SP 94.4%; area
under the curve 0.905; PTX3: SE 82.6%, SP 77.8%, area under the
curve 0.914).
Eight of 23 patients in the active phase had a negative hsCRP
level (1,734 ng/ml). Among these patients, we determined the
SP and SE of PTX3 (SE 75.0%, SP 76.5%). The PTX3 level was
increased in 6 of the 8 patients.
We examined the relationship between the prednisolone dose
and each biomarker. We found that there was a positive correlation
between the plasma MMP-3 level and the prednisolone dose.
However, PTX3 levels were not correlated with prednisolone dose
(MMP-3: R  0.649; PTX3: R  0.432).
PTX3 is more specific for arterial inflammation than CRP
because of the mechanism of induction and location of production.
We performed immunohistochemical staining of the aortic aneu-
rysm from patients with TA after surgery. Endothelial cells of the
vasa vasorum and inflammatory cells were positive for PTX3. One
of the histological features of TA is hyperplasia of vasa vasorum.
Therefore, it is reasonable that PTX3 is increased in the blood in
response to subtle vascular inflammation; however, further studies
are needed to investigate this.
The mechanisms by which steroids increase MMP-3 serum
levels remain unknown. However, determining the MMP-3 level
to assess TA disease activity should be done with caution. In
contrast, PTX3 level is not affected by prednisolone. Considering
the need for prednisolone in patients with TA, this evidence is very
important for assessing TA activity.
There are limitations to this study. The size of this study is
small, and the length of follow-up for these patients might not
be sufficiently long. More importantly, the relationship between
the long- or mid-term prognosis and the levels of these
biomarkers should be a subject of investigation, although it
takes many years.
We conclude that PTX3 could be a new and sensitive biomarker
to assess TA activity, which is not affected by prednisolone.
Moreover, this study could help to establish new and more accurate
criteria for assessing TA activity than National Institutes of Health
criteria, which are the only criteria that we could use.
P
M
t
R
1713JACC Vol. 57, No. 16, 2011 Correspondence
April 19, 2011:1712–6Takashi Ishihara, MD
Go Haraguchi, MD, PhD
Tetsuo Kamiishi, MD
Daisuke Tezuka, MD
Hiroshi Inagaki, MD, PhD
*Mitsuaki Isobe, MD, PhD
*Department of Cardiovascular Medicine
Tokyo Medical and Dental University
1-5-45 Yushima Bunkyo-ku
Tokyo 113-8519
Japan
E-mail: isobemi.cvm@tmd.ac.jp
Figure 1 Serum Levels of hsCRP, PTX3, MMP-3, and MMP-2 in Takayas
*According to 1-way analysis of variance with Games-Howel adjustment. p values
hsCRP  high-sensitive C-reactive protein; MMP  matrix metalloproteinase; PTX3doi:10.1016/j.jacc.2010.10.058
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You Should Take Into
Account Each Hospital
We read with interest the article by Freeman et al. (1). The authorscardioverter-defibrillator (ICD) implantation volume and proce-
dural complications.
They found that patients who have an ICD implanted at a
high-volume hospital are less likely to have an adverse event
associated with the procedure; patient data were collected from
1,201 different hospitals. An appropriate statistical method is
critical when investigating the impact of procedure volume onu’s A
0.05
 peclinical outcome. One-level hierarchical logistic regression to
